{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:39:12Z","timestamp":1793421552617,"version":"4.5.0"},"reference-count":142,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.bioorg.2024.107409","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T15:22:38Z","timestamp":1714404158000},"page":"107409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"C","title":["Sulfonamides as anticancer agents: A brief review on sulfonamide derivatives as inhibitors of various proteins overexpressed in cancer"],"prefix":"10.1016","volume":"147","author":[{"given":"Khaled A.","family":"Elsayad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada F.","family":"Elmasry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally T.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi M.","family":"Awadallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bioorg.2024.107409_b0005","article-title":"MRGCN: cancer subtyping with multi-reconstruction graph convolutional network using full and partial multi-omics dataset","volume":"39","author":"Yang","year":"2023","journal-title":"Bioinform Adv."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107409_b0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15020376","article-title":"The tumor microenvironment in tumorigenesis and therapy resistance revisited","volume":"15","author":"Dzobo","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2024.107409_b0015","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ejmech.2018.10.037","article-title":"Research advances on anticancer activities of matrine and its derivatives: An updated overview","volume":"161","author":"Rashid","year":"2019","journal-title":"Eur. J. Med. Chem. Rep."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107409_b0020","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12551-021-00795-9","article-title":"Sulfonamide drugs: Structure, antibacterial property, toxicity, and biophysical interactions","volume":"13","author":"Ovung","year":"2021","journal-title":"Biophys. Rev."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107409_b0025","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.2174\/1385272824999200515094100","article-title":"Sulfonamides: antiviral strategy for neglected tropical disease virus","volume":"24","author":"Dash","year":"2020","journal-title":"Curr. Org. Chem."},{"key":"10.1016\/j.bioorg.2024.107409_b0030","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00449-016-1699-1","article-title":"Distribution of sulfonamides in liquid and solid anaerobic digestates: effects of hydraulic retention time and swine manure to rice straw ratio","volume":"40","author":"Jin","year":"2017","journal-title":"Bioprocess Biosyst. Eng."},{"issue":"8","key":"10.1016\/j.bioorg.2024.107409_b0035","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1039\/C9NJ05612B","article-title":"On the in silico and in vitro anticancer activity of sulfonamide chalcones: Potential JNKK3 inhibitors","volume":"44","author":"Custodio","year":"2020","journal-title":"Njch."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107409_b0040","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/jleuko\/qiac015","article-title":"RNA splicing factors in normal hematopoiesis and hematologic malignancies: novel therapeutic targets and strategies","volume":"113","author":"Li","year":"2023","journal-title":"J. Leukoc. Biol. Suppl."},{"key":"10.1016\/j.bioorg.2024.107409_b0045","doi-asserted-by":"crossref","unstructured":"K. Szafra\u0144ski, J. S\u0142awi\u0144ski, \u0141. Tomorowicz, A. Kawiak: Synthesis, anticancer evaluation and structure-activity analysis of novel (E)-5-(2-arylvinyl)-1, 3, 4- oxadiazol-2-yl) benzenesulfonamides. nt. J. Mol. Sci. 2020, 21(6):2235.","DOI":"10.3390\/ijms21062235"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107409_b0050","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1515\/hc-2020-0008","article-title":"Coumarin sulfonamide derivatives: An emerging class of therapeutic agents","volume":"26","author":"Irfan","year":"2020","journal-title":"Heterocycl. Comm."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107409_b0055","first-page":"18","article-title":"Recent advances in development of sulfonamide derivatives and their pharmacological effects\u2014a review","volume":"3","author":"Ajeet","year":"2015","journal-title":"Am. J. Pharmacol. Sci."},{"key":"10.1016\/j.bioorg.2024.107409_b0060","unstructured":"Immunotherapy Combination Most Effective as Initial Treatment for BRAF+ Melanoma [https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2021\/advanced-melanoma-braf-immunotherapy-first]."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107409_b0065","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3390\/cancers15030918","article-title":"Vemurafenib and Dabrafenib Downregulates RIPK4 Level","volume":"15","author":"Madej","year":"2023","journal-title":"Cancers"},{"issue":"23","key":"10.1016\/j.bioorg.2024.107409_b0070","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2024.107409_b0075","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s11523-017-0511-8","article-title":"Pazopanib: a review in advanced renal cell carcinoma","volume":"12","author":"Frampton","year":"2017","journal-title":"Target. Oncol."},{"key":"10.1016\/j.bioorg.2024.107409_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40360-018-0264-8","article-title":"Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma","volume":"19","author":"M\u00e9ndez-Vidal","year":"2018","journal-title":"BMC Pharmacol. Toxicol."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107409_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.103025","article-title":"The aryl sulfonamide indisulam inhibits gastric cancer cell migration by promoting the ubiquitination and degradation of the transcription factor ZEB1","volume":"299","author":"Lu","year":"2023","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107409_b0090","article-title":"Genetic and compound screens uncover factors modulating cancer cell response to indisulam","volume":"5","author":"Pogacar","year":"2022","journal-title":"LSA."},{"issue":"18","key":"10.1016\/j.bioorg.2024.107409_b0095","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.4155\/fmc-2017-0136","article-title":"Routes to drug design via bioisosterism of carboxyl and sulfonamide groups","volume":"9","author":"Arabi","year":"2017","journal-title":"Future Med. Chem."},{"issue":"18","key":"10.1016\/j.bioorg.2024.107409_b0100","doi-asserted-by":"crossref","first-page":"6429","DOI":"10.1039\/D1SC01389K","article-title":"Photocatalytic decarboxylative amidosulfonation enables direct transformation of carboxylic acids to sulfonamides","volume":"12","author":"Nguyen","year":"2021","journal-title":"Chem. Sci."},{"key":"10.1016\/j.bioorg.2024.107409_b0105","article-title":"Sulfonamide derivatives as potential anti-cancer agents and their SARs elucidation","volume":"226","author":"Wan","year":"2021","journal-title":"Eur. J. Med. Chem. Rep."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107409_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43042-019-0035-0","article-title":"Exploring receptor tyrosine kinases-inhibitors in Cancer treatments","volume":"20","author":"Metibemu","year":"2019","journal-title":"Egypt. J. Med. Hum. Genet."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107409_b0115","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.drudis.2021.12.009","article-title":"A molecular perspective for the use of type IV tyrosine kinase inhibitors as anticancer therapeutics","volume":"27","author":"Das","year":"2022","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107409_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0788-y","article-title":"Role of non receptor tyrosine kinases in hematological malignances and its targeting by natural products","volume":"17","author":"Siveen","year":"2018","journal-title":"Mol. Cancer"},{"issue":"772510","key":"10.1016\/j.bioorg.2024.107409_b0125","article-title":"Receptor tyrosine kinases and their signaling pathways as therapeutic targets of curcumin in cancer","volume":"12","author":"Dev","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2024.107409_b0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0782-4","article-title":"Mechanisms of receptor tyrosine kinase activation in cancer","volume":"17","author":"Du","year":"2018","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.bioorg.2024.107409_b0135","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.3390\/ijms24043469","article-title":"Blood Inflammatory-like and Lung Resident-like Eosinophils Affect Migration of Airway Smooth Muscle Cells and Their ECMRelated Proliferation in Asthma","volume":"24","author":"Rimkunas","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.bioorg.2024.107409_b0140","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.3390\/ijms22126342","article-title":"All good things must end: Termination of receptor tyrosine kinase signal","volume":"22","author":"Margiotta","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.107409_b0145","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.3389\/fonc.2020.01642","article-title":"Receptor tyrosine kinases in osteosarcoma treatment: which is the key target?","volume":"10","author":"Tian","year":"2020","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107409_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43094-021-00346-9","article-title":"Receptor tyrosine kinases as a therapeutic target by natural compounds in cancer treatment","volume":"7","author":"Balogun","year":"2021","journal-title":"Futur. J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2024.107409_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12864-017-3948-3","article-title":"Expansion and evolutionary patterns of cysteine-rich peptides in plants","volume":"18","author":"Liu","year":"2017","journal-title":"BMC Genomics"},{"issue":"9","key":"10.1016\/j.bioorg.2024.107409_b0160","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.210218","article-title":"The multifaceted role of lemur tyrosine kinase 3 in health and disease","volume":"11","author":"Ditsiou","year":"2021","journal-title":"Open Biol."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107409_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127108","article-title":"Discovery of cyclic guanidine-linked sulfonamides as inhibitors of LMTK3 kinase","volume":"30","author":"Ortiz","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107409_b0170","unstructured":"H. Sarma: In silico Study on the Structure and Dynamics of Human Lemur Tyrosine Kinase-3 (LMTK3): A new Potential Target for Breast Cancer. TU.; 2018."},{"key":"10.1016\/j.bioorg.2024.107409_b0175","doi-asserted-by":"crossref","unstructured":"E. Levantini, G. Maroni, M. Del Re, D.G. Tenen: EGFR signaling pathway as therapeutic target in human cancers. In: Semin Cancer Biol. 2022: Elsevier; 2022: 253-275.","DOI":"10.1016\/j.semcancer.2022.04.002"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107409_b0180","first-page":"1","article-title":"The role of epigenetic modifications in drug resistance and treatment of breast cancer","volume":"27","author":"Fath","year":"2022","journal-title":"Cell. Mol. Biol. Lett."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107409_b0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0793-1","article-title":"EGFR-TKIs resistance via EGFRindependent signaling pathways","volume":"17","author":"Liu","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2024.107409_b0190","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3389\/fphar.2015.00283","article-title":"Role of ErbB receptors in cancer cell migration and invasion","volume":"6","author":"Appert-Collin","year":"2015","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107409_b0195","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3390\/ijms20051033","article-title":"A review of curcumin and its derivatives as anticancer agents","volume":"20","author":"Tomeh","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107409_b0200","article-title":"Yang: Stratification of non-small cell lung adenocarcinoma patients with EGFR actionable mutations based on drug-resistant stem cell genes","volume":"26","author":"Xie","year":"2023","journal-title":"iSci"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107409_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yexcr.2018.08.009","article-title":"Epidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics","volume":"371","author":"Mitchell","year":"2018","journal-title":"Exp. Cell Res."},{"issue":"21","key":"10.1016\/j.bioorg.2024.107409_b0210","doi-asserted-by":"crossref","first-page":"11125","DOI":"10.1080\/07391102.2021.1956591","article-title":"Identification of the structural features of quinazoline derivatives as EGFR inhibitors using 3D-QSAR modeling, molecular docking, molecular dynamics simulations and free energy calculations","volume":"40","author":"Wang","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107409_b0215","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.3390\/ijms21051721","article-title":"Conformational insight on WT-and mutated-EGFR receptor activation and inhibition by epigallocatechin-3- gallate: Over a rational basis for the design of selective non-small-cell lung anticancer agents","volume":"21","author":"Minnelli","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.107409_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105164","article-title":"Natural tyrosine kinase inhibitors acting on the epidermal growth factor receptor: Their relevance for cancer therapy","volume":"161","author":"Liang","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107409_b0225","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1021\/acs.jmedchem.2c01434","article-title":"Development of furanopyrimidine-based orally active third-generation EGFR inhibitors for the treatment of non-small cell lung cancer","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107409_b0230","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1080\/14756366.2019.1609469","article-title":"Novel sulfonamide benzoquinazolinones as dual EGFR\/HER2 inhibitors, apoptosis inducers and radiosensitizers","volume":"34","author":"Soliman","year":"2019","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107409_b0235","article-title":"Sulfonamides modulating tyrosine kinases-An expedient approach towards novel anticancer agents","volume":"100950","author":"Das","year":"2023","journal-title":"Results Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2024.107409_b0240","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.3390\/ijms23073487","article-title":"Hybrid pharmacophore-and structure-based virtual screening pipeline to identify novel EGFR inhibitors that suppress non-small cell lung cancer cell growth","volume":"23","author":"Weng","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.107409_b0245","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.687458","article-title":"Targeting Bruton\u2019s tyrosine kinase in CLL","volume":"12","author":"Ahn","year":"2021","journal-title":"Front. Immunol."},{"issue":"109956","key":"10.1016\/j.bioorg.2024.107409_b0250","article-title":"Bioactive sulfonyl hydrazones with alkyl derivative: Characterization, ADME properties, molecular docking studies and investigation of inhibition on choline esterase enzymes for the diagnosis of Alzheimer's disease","volume":"360","author":"Bilen","year":"2022","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bioorg.2024.107409_b0255","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejmech.2017.04.037","article-title":"Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFADPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia","volume":"135","author":"Liu","year":"2017","journal-title":"Eur. J. Med. Chem. Rep."},{"key":"10.1016\/j.bioorg.2024.107409_b0260","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev-cancerbio-051420-114114","article-title":"Small molecule approaches to targeted protein degradation","volume":"5","author":"Faust","year":"2021","journal-title":"Annu. Rev. Cancer Biol."},{"issue":"26","key":"10.1016\/j.bioorg.2024.107409_b0265","doi-asserted-by":"crossref","first-page":"7919","DOI":"10.1002\/slct.202001449","article-title":"Design and Synthesis of Sulfonamide- Attached 2-(Isoxazol-3-yl)-1H-imidazoles as Anticancer Agents","volume":"5","author":"Dende","year":"2020","journal-title":"ChemistrySelect"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107409_b0270","doi-asserted-by":"crossref","first-page":"e0147190","DOI":"10.1371\/journal.pone.0147190","article-title":"Woo Lee: Exploration of novel inhibitors for Bruton\u2019s tyrosine kinase by 3D QSAR modeling and molecular dynamics simulation","volume":"11","author":"Bavi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2024.107409_b0275","unstructured":"Key Statistics for Breast Cancer [https:\/\/www.cancer.org\/cancer\/types\/breast-cancer\/about\/how-common-is-breast-cancer.html]."},{"key":"10.1016\/j.bioorg.2024.107409_b0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-021-01462-3","article-title":"ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer","volume":"23","author":"Brett","year":"2021","journal-title":"Breast Cancer Res."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107409_b0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-018-0116-7","article-title":"Mechanisms for estrogen receptor expression in human cancer","volume":"7","author":"Hua","year":"2018","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2024.107409_b0290","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s11030-020-10133-y","article-title":"Most recent strategies targeting estrogen receptor alpha for the treatment of breast cancer","volume":"25","author":"Kumar","year":"2021","journal-title":"Mol. Divers."},{"key":"10.1016\/j.bioorg.2024.107409_b0295","article-title":"Molecular mechanisms of endocrine resistance in estrogen-receptor-positive breast Cancer","volume":"12","author":"Belachew","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107409_b0300","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.3390\/molecules28062490","article-title":"Virtual Screening for Identification of Dual Inhibitors against CDK4\/6 and Aromatase Enzyme","volume":"28","author":"Adon","year":"2023","journal-title":"Molecules"},{"issue":"10","key":"10.1016\/j.bioorg.2024.107409_b0305","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3390\/ph14100984","article-title":"Design, synthesis and biological evaluation of aromatase inhibitors based on sulfonates and sulfonamides of resveratrol","volume":"14","author":"Fantacuzzi","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"5","key":"10.1016\/j.bioorg.2024.107409_b0310","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3390\/md21050308","article-title":"Advanced Methods for Natural Products Discovery: Bioactivity Screening, 41 Dereplication, Metabolomics Profiling, Genomic Sequencing, Databases and Informatic Tools, and Structure Elucidation","volume":"21","author":"Gaud\u00eancio","year":"2023","journal-title":"Mar. Drugs"},{"issue":"3","key":"10.1016\/j.bioorg.2024.107409_b0315","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","article-title":"Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019","volume":"83","author":"Newman","year":"2020","journal-title":"J. Nat. Prod."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107409_b0320","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3390\/molecules29020346","article-title":"Aromatase Inhibitors as a Promising Direction for the Search for New Anticancer Drugs","volume":"29","author":"Janowska","year":"2024","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107409_b0325","first-page":"1","article-title":"Synthesis of biologically active sulfonamide-based indole analogs: a review","volume":"9","author":"Mushtaq","year":"2023","journal-title":"Future J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107409_b0330","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13046-023-02724-y","article-title":"Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance","volume":"42","author":"Kao","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107409_b0335","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3390\/ijms20030535","article-title":"The effects of resveratrol in the treatment of metabolic syndrome","volume":"20","author":"Hou","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107409_b0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-021-02179-1","article-title":"STAT3 pathway as a molecular target for resveratrol in breast cancer treatment","volume":"21","author":"Kohandel","year":"2021","journal-title":"Cancer Cell Int."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107409_b0345","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.3390\/ijms20061381","article-title":"Progress to improve oral bioavailability and beneficial effects of resveratrol","volume":"20","author":"Chimento","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107409_b0350","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3390\/nu11010143","article-title":"Resveratrol and its human metabolites\u2014effects on metabolic health and obesity","volume":"11","author":"Springer","year":"2019","journal-title":"Nutrients"},{"issue":"13","key":"10.1016\/j.bioorg.2024.107409_b0355","doi-asserted-by":"crossref","first-page":"7273","DOI":"10.3390\/ijms23137273","article-title":"Oxidative stress in ageing and chronic degenerative pathologies: molecular mechanisms involved in counteracting oxidative stress and chronic inflammation","volume":"23","author":"Leyane","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107409_b0360","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/jsfa.10152","article-title":"Resveratrol: A review of plant sources, synthesis, stability, modification and food application","volume":"100","author":"Tian","year":"2020","journal-title":"J. Sci. Food Agric."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107409_b0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13765-021-00607-4","article-title":"Biosynthesis of resveratrol derivatives and evaluation of their anti-inflammatory activity","volume":"64","author":"Chong","year":"2021","journal-title":"Appl. Biol. Chem."},{"key":"10.1016\/j.bioorg.2024.107409_b0370","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1007\/s00044-019-02351-3","article-title":"Synthesis and cytotoxic effects on pancreatic cancer cells of resveratrol analogs","volume":"28","author":"De Filippis","year":"2019","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bioorg.2024.107409_b0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113737","article-title":"Cataldi: Synthesis, structure-activity relationships and molecular docking studies of phenyldiazenyl sulfonamides as aromatase inhibitors","volume":"224","author":"Giampietro","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2024.107409_b0380","doi-asserted-by":"crossref","first-page":"2000081","DOI":"10.1002\/ardp.202000081","article-title":"Aromatase inhibitors: Role in postmenopausal breast cancer","volume":"353","author":"Kharb","year":"2020","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2024.107409_b0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111815","article-title":"Synthesis, biological evaluation, and docking study of indole aryl sulfonamides as aromatase inhibitors","volume":"185","author":"Fantacuzzi","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2024.107409_b0390","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1039\/D2OB02134J","article-title":"Addition of sulfonylphthalides to para-quinone methides: Selective 1, 6-additions and oxidative annulations","volume":"21","author":"Gond","year":"2023","journal-title":"Org. Biomol. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2024.107409_b0395","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1080\/17460441.2021.1916464","article-title":"Murugesan: 1, 2, 3, 4-Tetrahydroisoquinoline (THIQ) as privileged scaffold for anticancer de novo drug design","volume":"16","author":"Faheem","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"issue":"15","key":"10.1016\/j.bioorg.2024.107409_b0400","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.3390\/ijms20153841","article-title":"Role of carbonic anhydrases and inhibitors in acid\u2013 base physiology: insights from mathematical modeling","volume":"20","author":"Occhipinti","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.107409_b0405","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.772278","article-title":"Carbonic anhydrases as potential targets against neurovascular unit dysfunction in Alzheimer\u2019s disease and stroke","volume":"13","author":"Lemon","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.bioorg.2024.107409_b0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104347","article-title":"Discovery of novel artemisinin-sulfonamide hybrids as potential carbonic anhydrase IX inhibitors with improved antiproliferative activities","volume":"104","author":"An","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2024.107409_b0415","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00249-021-01561-1","article-title":"Structure and mechanism of secondary sulfonamide binding to carbonic anhydrases","volume":"50","author":"Baronas","year":"2021","journal-title":"Eur. Biophys. J."},{"key":"10.1016\/j.bioorg.2024.107409_b0420","article-title":"The pyridazine heterocycle in molecular recognition and drug discovery","volume":"1\u201369","author":"Meanwell","year":"2023","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bioorg.2024.107409_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.131145","article-title":"Designing novel anticancer sulfonamide based 2, 5- disubstituted-1, 3, 4-thiadiazole derivatives as potential carbonic anhydrase inhibitor","volume":"1246","author":"Abas","year":"2021","journal-title":"J. Mol. Struct."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107409_b0430","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3390\/ijms23020957","article-title":"Comparison of carbonic anhydrases for CO2 sequestration","volume":"23","author":"Steger","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.107409_b0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105920","article-title":"A decade of tail-approach based design of selective as well as potent tumor associated carbonic anhydrase inhibitors","volume":"126","author":"Kumar","year":"2022","journal-title":"Bioorg. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107409_b0440","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/ep.12394","article-title":"Role of carbonic anhydrase on the way to biological carbon capture through microalgae\u2014a mini review","volume":"35","author":"Mondal","year":"2016","journal-title":"Environ. Prog. Sustain. Energy"},{"issue":"11","key":"10.1016\/j.bioorg.2024.107409_b0445","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3390\/biom12111696","article-title":"Design, synthesis, kinetic analysis and pharmacophore-directed discovery of 3-ethylaniline hybrid imino-thiazolidinone as potential inhibitor of carbonic anhydrase II: an emerging biological target for treatment of cancer","volume":"12","author":"Ahmed","year":"2022","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107409_b0450","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1107\/S2052252517017626","article-title":"Active-site solvent replenishment observed during human carbonic anhydrase II catalysis","volume":"5","author":"Kim","year":"2018","journal-title":"IUCrJ"},{"key":"10.1016\/j.bioorg.2024.107409_b0455","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.629163","article-title":"Carbonic anhydrases: new perspectives on protein functional role and inhibition in Helicobacter pylori","volume":"12","author":"Campestre","year":"2021","journal-title":"Front. Microbiol."},{"issue":"27","key":"10.1016\/j.bioorg.2024.107409_b0460","doi-asserted-by":"crossref","first-page":"18461","DOI":"10.1039\/D3RA03276K","article-title":"Synthesis, characterization and biological evaluation of pyrazole- 43 based benzene sulfonamides as inhibitors of human carbonic anhydrase II","volume":"13","author":"Hussain","year":"2023","journal-title":"IX and XII. RSC Adv."},{"issue":"42","key":"10.1016\/j.bioorg.2024.107409_b0465","doi-asserted-by":"crossref","first-page":"26241","DOI":"10.1039\/D1RA05277B","article-title":"Design, synthesis and mechanistic study of new benzenesulfonamide derivatives as anticancer and antimicrobial agents via carbonic anhydrase IX inhibition","volume":"11","author":"Nemr","year":"2021","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2024.107409_b0470","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1007\/s11224-021-01741-x","article-title":"Theoretical investigation of the structural and electronic features of SLC-0111, a novel inhibitor of human carbonic anhydrase IX, and its anion","volume":"32","author":"Chahal","year":"2021","journal-title":"Struct. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2024.107409_b0475","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3390\/md20110721","article-title":"Carbonic anhydrase inhibitors from marine natural products","volume":"20","author":"Supuran","year":"2022","journal-title":"Mar. Drugs"},{"issue":"11","key":"10.1016\/j.bioorg.2024.107409_b0480","doi-asserted-by":"crossref","first-page":"5462","DOI":"10.1021\/acs.jmedchem.6b00443","article-title":"An unusual natural product primary sulfonamide: synthesis, carbonic anhydrase inhibition, and protein X-ray structures of Psammaplin C","volume":"59","author":"Mujumdar","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107409_b0485","article-title":"Experimental carbonic anhydrase inhibitors for the treatment of hypoxic tumors","volume":"603\u2013617","author":"Supuran","year":"2020","journal-title":"J. Exp. Pharmacol."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107409_b0490","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11094-022-02597-z","article-title":"Piperazine heterocycles as potential anticancer agents: a review","volume":"56","author":"Al-Ghorbani","year":"2022","journal-title":"Pharm. Chem. J."},{"key":"10.1016\/j.bioorg.2024.107409_b0495","doi-asserted-by":"crossref","DOI":"10.1021\/acsmedchemlett.3c00094","article-title":"Discovery of Novel Hydroxyimine-Tethered Benzenesulfonamides as Potential Human Carbonic Anhydrase IX\/XII Inhibitors","author":"Peerzada","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"issue":"23","key":"10.1016\/j.bioorg.2024.107409_b0500","doi-asserted-by":"crossref","first-page":"7782","DOI":"10.3390\/molecules28237782","article-title":"Ureidobenzenesulfonamides as Selective Carbonic Anhydrase I, IX, and XII Inhibitors","volume":"28","author":"Denner","year":"2023","journal-title":"Molecules"},{"issue":"13","key":"10.1016\/j.bioorg.2024.107409_b0505","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.3390\/molecules24132418","article-title":"Synthesis, molecular docking analysis, and carbonic anhydrase inhibitory evaluations of benzenesulfonamide derivatives containing thiazolidinone","volume":"24","author":"Zhang","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2024.107409_b0510","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1007\/s00044-011-9868-x","article-title":"Pharmacophore modeling, virtual screening, and molecular docking studies for discovery of novel Carbonic anhydrase IX inhibitors","volume":"21","author":"Lu","year":"2012","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bioorg.2024.107409_b0515","doi-asserted-by":"crossref","unstructured":"M. Al-Sanea, G. Chilingaryan, N. Abelyan, G. Arakelov, H. Sahakyan, V. Arakelov, S. Hussein, G. Alazmi, H. Alsharari, W. Al-faraj: Virtual screening of the potential hCA XII inhibitors based on the pharmacophore modelling, molecular docking, MMGBSA and molecular dynamics simulations studies. 2021.","DOI":"10.21203\/rs.3.rs-394808\/v1"},{"key":"10.1016\/j.bioorg.2024.107409_b0520","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3389\/fmolb.2015.00019","article-title":"Multifaceted role of matrix metalloproteinases (MMPs)","volume":"2","author":"Singh","year":"2015","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.bioorg.2024.107409_b0525","first-page":"1","article-title":"Development of Matrix MetalloproteinasesMediated Extracellular Matrix Remodeling in Regenerative Medicine: A Mini Review. Tissue Eng","author":"Chen","year":"2023","journal-title":"Regen. Med."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107409_b0530","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1158\/1535-7163.MCT-17-0646","article-title":"Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes","volume":"17","author":"Winer","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107409_b0535","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1183\/09031936.00146510","article-title":"Biological role of matrix metalloproteinases: a critical balance","volume":"38","author":"L\u00f6ffek","year":"2011","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.bioorg.2024.107409_b0540","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3389\/fchem.2020.00402","article-title":"Zinc-containing metalloenzymes: inhibition by metal-based anticancer agents","volume":"8","author":"Ye","year":"2020","journal-title":"Front. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107409_b0545","doi-asserted-by":"crossref","first-page":"6525","DOI":"10.1007\/s11033-021-06635-z","article-title":"Matrix metalloproteinase contribution in management of cancer proliferation, metastasis and drug targeting","volume":"48","author":"Abdel-Hamid","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.bioorg.2024.107409_b0550","doi-asserted-by":"crossref","unstructured":"Q. Zhou, J. Xiang, N. Qiu, Y. Wang, Y. Piao, S. Shao, J. Tang, Z. Zhou, Y. Shen: Tumor Abnormality-Oriented Nanomedicine Design. Chem. Rev. 2023.","DOI":"10.1021\/acs.chemrev.3c00062"},{"key":"10.1016\/j.bioorg.2024.107409_b0555","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejmech.2017.02.014","article-title":"Arylsulfonamides and selectivity of matrix metalloproteinase-2: An overview","volume":"129","author":"Adhikari","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107409_b0560","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1039\/C5MB00003C","article-title":"Understanding the binding of inhibitors of matrix metalloproteinases by molecular docking, quantum mechanical calculations, molecular dynamics simulations, and a MMGBSA\/MMBappl study","volume":"11","author":"Singh","year":"2015","journal-title":"Mol. Biosyst."},{"issue":"17","key":"10.1016\/j.bioorg.2024.107409_b0565","doi-asserted-by":"crossref","first-page":"12603","DOI":"10.1021\/acs.jmedchem.1c00497","article-title":"Multifunctional arylsulfone and arylsulfonamide-based ligands with prominent mood-modulating activity and benign safety profile, targeting neuropsychiatric symptoms of dementia","volume":"64","author":"Marcinkowska","year":"2021","journal-title":"J. Med. Chem."},{"issue":"918789","key":"10.1016\/j.bioorg.2024.107409_b0570","article-title":"Nanotechnology and matrix metalloproteinases in cancer diagnosis and treatment","volume":"9","author":"Gonzalez-Avila","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.bioorg.2024.107409_b0575","article-title":"Influence of NArylsulfonamido d-Valine N-Substituents on the Selectivity and Potency of Matrix Metalloproteinase Inhibitors","volume":"117350","author":"Konken","year":"2023","journal-title":"Bioorg. Med. Chem."},{"issue":"16","key":"10.1016\/j.bioorg.2024.107409_b0580","doi-asserted-by":"crossref","first-page":"10709","DOI":"10.1021\/acs.jmedchem.1c01855","article-title":"Selective Inhibitors of MediumSize S1\u2032 Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery","volume":"65","author":"Baidya","year":"2022","journal-title":"J. Med. Chem."},{"issue":"26","key":"10.1016\/j.bioorg.2024.107409_b0585","first-page":"7888","article-title":"Understanding Chemico-Biological Interactions of Glutamate MMP-2 Inhibitors through Rigorous Alignment-Dependent 3D-QSAR Analyses","volume":"2","author":"Adhikari","year":"2017","journal-title":"Chem. Select"},{"key":"10.1016\/j.bioorg.2024.107409_b0590","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10822-017-0028-3","article-title":"Multiple receptor-ligand based pharmacophore modeling and molecular docking to screen the selective inhibitors of matrix metalloproteinase-9 from natural products","volume":"31","author":"Gao","year":"2017","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.bioorg.2024.107409_b0595","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.700947","article-title":"Characterization of histone deacetylase mechanisms in cancer development","volume":"11","author":"Hai","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2024.107409_b0600","article-title":"The roles of histone deacetylases and their inhibitors in cancer therapy","volume":"8","author":"Li","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"7","key":"10.1016\/j.bioorg.2024.107409_b0605","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1007\/s12094-022-02779-x","article-title":"Insights into the therapeutic potential of histone deacetylase inhibitor\/immunotherapy combination regimens in solid tumors","volume":"24","author":"Sedky","year":"2022","journal-title":"Clin. Transl. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107409_b0610","first-page":"1","article-title":"Histone deacetylase 6 in cancer","volume":"11","author":"Li","year":"2018","journal-title":"BioMed Central Ltd."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107409_b0615","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.3390\/ijms24054263","article-title":"Histone Deacetylases (HDACs): Promising Biomarkers and Potential Therapeutic Targets in Thymic Epithelial Tumors","volume":"24","author":"Palamaris","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107409_b0620","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.3390\/ijms24054306","article-title":"Histone Deacetylases: Molecular Mechanisms and Therapeutic Implications for Muscular Dystrophies","volume":"24","author":"Sandon\u00e0","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.107409_b0625","first-page":"1","article-title":"Role of HDACs in normal and malignant hematopoiesis","volume":"19","author":"Wang","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2024.107409_b0630","article-title":"Recent update of HDAC inhibitors in lymphoma","volume":"8","author":"Chen","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"15","key":"10.1016\/j.bioorg.2024.107409_b0635","doi-asserted-by":"crossref","first-page":"8141","DOI":"10.3390\/ijms23158141","article-title":"The role of HDACs in the response of cancer cells to cellular stress and the potential for therapeutic intervention","volume":"23","author":"Alseksek","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.bioorg.2024.107409_b0640","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1158\/0008-5472.CAN-20-3044","article-title":"HDAC11 regulates glycolysis through the LKB1\/AMPK signaling pathway to maintain hepatocellular carcinoma stemness","volume":"81","author":"Bi","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2024.107409_b0645","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fonc.2018.00092","article-title":"Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi","volume":"8","author":"Suraweera","year":"2018","journal-title":"Front. Oncol."},{"issue":"21","key":"10.1016\/j.bioorg.2024.107409_b0650","doi-asserted-by":"crossref","first-page":"12460","DOI":"10.1021\/acs.jmedchem.0c00830","article-title":"Thirty years of HDAC inhibitors: 2020 insight and hindsight","volume":"63","author":"Ho","year":"2020","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107409_b0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.jscs.2022.101450","article-title":"Design, synthesis, and biological evaluation of novel histone deacetylase 6 selective inhibitors","volume":"26","author":"Zhang","year":"2022","journal-title":"J. Saudi Chem. Soc."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107409_b0660","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s13402-022-00704-6","article-title":"HDAC6: A unique HDAC family member as a cancer target","volume":"45","author":"Kaur","year":"2022","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.bioorg.2024.107409_b0665","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.719390","article-title":"Role of HDAC6 and its selective inhibitors in gastrointestinal cancer","volume":"9","author":"Zhou","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bioorg.2024.107409_b0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103262","article-title":"First example of Azo-Sulfa conjugated chromene moieties: Synthesis, characterization, antimicrobial assessment, docking simulation as potent class I histone deacetylase inhibitors and antitumor agents","volume":"92","author":"Okasha","year":"2019","journal-title":"Bioorg. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107409_b0675","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.3390\/ijms22062807","article-title":"Hagar M: A new family of benzo [h] chromene based azo dye: synthesis, in-silico and DFT studies with in vitro antimicrobial and antiproliferative assessment","volume":"22","author":"Abd-El-Aziz","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.107409_b0680","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3389\/fchem.2020.00623","article-title":"2H\/4H-Chromenes\u2014A versatile biologically attractive Scaffold","volume":"8","author":"Raj","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.bioorg.2024.107409_b0685","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11094-020-02187-x","article-title":"Saleem: Current strategies in development of new chromone derivatives with diversified pharmacological activities: a review","volume":"54","author":"Nu","year":"2020","journal-title":"Pharm. Chem. J."},{"key":"10.1016\/j.bioorg.2024.107409_b0690","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-981-15-2361-8_8","article-title":"Chromenes: phytomolecules with immense therapeutic potential","author":"Hussain","year":"2020","journal-title":"Plant-Derived Bioact. Chem. Mode Action."},{"issue":"40","key":"10.1016\/j.bioorg.2024.107409_b0695","doi-asserted-by":"crossref","first-page":"25932","DOI":"10.1039\/D2RA04934A","article-title":"Synthesis and pharmacological activities of azo dye derivatives incorporating heterocyclic scaffolds: a review","volume":"12","author":"Mezgebe","year":"2022","journal-title":"RSC Adv."},{"issue":"8","key":"10.1016\/j.bioorg.2024.107409_b0700","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.3390\/molecules25081952","article-title":"Computer-driven development of an in silico tool for finding selective histone deacetylase 1 inhibitors","volume":"25","author":"Sirous","year":"2020","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.bioorg.2024.107409_b0705","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00894-022-05103-0","article-title":"Identification of potent HDAC 2 inhibitors using E-pharmacophore modelling, structure-based virtual screening and molecular dynamic simulation","volume":"28","author":"Pai","year":"2022","journal-title":"J. Mol. Model."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107409_b0710","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1021\/ci500762z","article-title":"Enhancing the sensitivity of pharmacophore-based virtual screening by incorporating customized ZBG features: a case study using histone deacetylase 8","volume":"55","author":"Hou","year":"2015","journal-title":"J. Chem. Inf. Model."}],"updated-by":[{"DOI":"10.1016\/j.bioorg.2024.107583","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000}}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824003146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824003146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T09:06:16Z","timestamp":1715677576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206824003146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":142,"alternative-id":["S0045206824003146"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107409","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.bioorg.2024.107583","asserted-by":"object"}]},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sulfonamides as anticancer agents: A brief review on sulfonamide derivatives as inhibitors of various proteins overexpressed in cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107409","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107409"}}